Mirum Pharmaceuticals Inc. (MIRM)
NASDAQ: MIRMHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MIRM stock chart
Technical analysisKey statistics
All statistics- Market cap
- $5.24B
- EPS (TTM)
- -$14.10
- Dividend yield
- None
- 52-week range
- 63.23 – 130.00
- Day range
- 78.77 – 83.13
- Volume / Avg
- 1.02M / 693.63K
- Beta
- —
- Shares outstanding
- 64.93M
- Next earnings
- Nov 3, 2026
52-week range
MIRM stock today
Mirum Pharmaceuticals (MIRM) closed at $80.64 on Oct 7, up 1.75% (+$1.39), versus the S&P 500's 0.22% decline. Shares are 38.0% below their 52-week high of $130.00, set on Jul 9, 2026 and 27.5% above the 52-week low of $63.23, in the middle of the past year's range. MIRM is up 2.1% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 9.4%.
Mirum Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$14.10), so its P/E ratio is not meaningful. Mirum Pharmaceuticals's next earnings report is expected on Nov 3, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Mirum Pharmaceuticals
Company profileMirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under development for the treatment cerebrotendinous xanthomatosis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Christopher Peetz
- Headquarters
- Foster City, CA
- Employees
- 433
- IPO year
- 2019
- Website
- mirumpharma.com
Financial highlights
Full financialsIn fiscal 2025, Mirum Pharmaceuticals generated $521.3 million in revenue, up 54.7% from fiscal 2024, its 5th consecutive year of revenue growth. Mirum Pharmaceuticals reported a net loss of $23.4 million, compared with a loss of $87.9 million a year earlier. Operating margin was -4.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $521.31M | $336.89M | $186.37M | $77.06M | $19.14M |
| Growth | +54.74% | +80.76% | +141.85% | +302.66% | — |
| Net income | $-23.36M | $-87.94M | $-163.41M | $-135.66M | $-83.99M |
| EPS (diluted) | $-0.47 | $-1.85 | $-4.00 | $-4.02 | $-2.77 |
Analyst forecast
ForecastConsensus (14 analysts)
strong_buy
Avg. price target
$145.79+80.79%
- Strong buy 4
- Buy 10
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 3, 2026
- EPS estimate
- $-0.53
- Last reported (Q2 2026)
- Aug 5, 2026
- EPS actual vs est.
- $-1.06 vs —
MIRM news
All MIRM newsMirum Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GRFSGrifols S.A. ADR | 7.50 | -0.27% | $5.10B | vs MIRM |
| COGTCogent Biosciences Inc. | 30.14 | -0.79% | $5.23B | vs MIRM |
| TVTXTravere Therapeutics Inc. | 53.44 | -4.54% | $5.04B | vs MIRM |
| PTCTPTC Therapeutics Inc. | 63.23 | -0.74% | $5.28B | vs MIRM |
| ERASErasca Inc. | 14.12 | -1.26% | $4.94B | vs MIRM |
| MANEVeradermics Incorporated | 110.95 | +1.83% | $4.64B | vs MIRM |
| LGNDLigand Pharmaceuticals Incorporated | 293.26 | -1.24% | $5.85B | vs MIRM |
| EWTXEdgewise Therapeutics Inc. | 39.57 | -1.12% | $4.30B | vs MIRM |
Indexes, lists and sector
Mirum Pharmaceuticals stock FAQ
What is Mirum Pharmaceuticals's stock price today?
MIRM last traded at $80.64 as of Oct 7, 4:00 PM EDT, up 1.75% on the day. Prices are delayed at least 15 minutes.
When is Mirum Pharmaceuticals's next earnings date?
Mirum Pharmaceuticals is expected to report earnings on Tuesday, November 3, 2026. Analysts expect EPS of $-0.53.
Who is Mirum Pharmaceuticals's CEO?
Mr. Christopher Peetz is the chief executive officer of Mirum Pharmaceuticals Inc., which has about 433 employees.
What is the MIRM 52-week high?
The 52-week high for MIRM is $130.00 and the 52-week low is $63.23. The stock is currently 38.0% below its high.